
Opinion|Videos|October 9, 2023
Untapped Potentials - Exploring Overlooked Therapies for Type 2 Diabetes
In this episode of MEDcast, the expert panelists examine some underutilized therapies in type 2 diabetes (T2D) and explore their potential as effective treatment choices for many patients.
Advertisement
Episodes in this series
0:50 Need for using older diabetes medications
3:30 Quick-release bromocriptine: benefits in T2D and cardiovascular risk
6:15 Efficacy of quick-release bromocriptine
8:10 Quick-release bromocriptine as monotherapy and as an add-on
9:00 Mechanism of quick-release bromocriptine
11:41 Titrating quick-release bromocriptine
15:50 Benefits of pioglitazone
22:30 Positioning older T2D therapies in the current treatment regimen
Advertisement
Related to this article

TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.

Tom Martens, MD, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss CONNECT trial data on CGM in non-insulin-treated type 2 diabetes.

Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.
Advertisement
Advertisement
Trending on HCPLive
1
Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD
2
ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema
3
Omalizumab Linked to 0 Epinephrine Use in Alpha-Gal Syndrome
4
Early Dupilumab in Pediatric EoE Tied to Lower Incident Asthma
5


